米索前列醇后穹窿给药用于足月妊娠引产

目的探讨足月妊娠应用米索前列醇引产的安全性和效果.方法选择正常单胎头位足月妊娠具有引产指征,而无禁忌症100例,随机分成两组,米索组用米索前列醇50μg放置阴道后穹窿,每3h服1次,共3次,缩宫素组用缩宫素2.5IU加入5%葡萄糖500ml内.结果米索组引产的有效率为95.46%,缩宫素组为80.85%,P＜0.05,有显著差异,低宫颈评分引产成功率,米索组84.09%,缩宫素组48.94%,P＜0.05,有显著差异,总产程时间米索组短于缩宫素组,二组分娩方式、产后出血、以及新生儿情况比较无显著差异.结论米索前列醇应用于足月妊娠引产既能促宫颈成熟,又能于短时间内发动规律宫缩,两者同步化,是一种使用方便、安全有效、价格便宜的引产方法,但需严密监护.     

米索前列醇阴道给药用于足月妊娠引产的临床观察

米索前列醇（Ｍｉｓｏ）既保存前列腺素Ｅ１（ＰＧＥ１）的活性,又克服了天然ＰＧＥ１的缺点,其作用较ＰＧ０５即卡波前列甲醇（ｃɑｒｂｏｐｒｏｓｔｍｅｔｈｙｌ）弱（１）。配伍米非司酮（Ｍｉｆｅ）用于早、中孕药物流产,临床效果满意。Ｒｅｆɑｅｙ等报道阴道给药...     

米索前列醇用于足月妊娠引产不同给药途径的临床观察

目的为了观察米索前列醇(Misoprostol,米索)用于足月妊娠引产不同给药途径(舌下含服及阴道后穹窿给药)的临床效果.方法选择有引产指征,无引产及米索使用禁忌症的单胎、头位的足月妊娠妇女72例,随机分为A组(舌下含服组)、B组(阴道后穹窿组),分别用米索50μg舌下含服及阴道后穹窿给药,间隔4～6h重复给药,24h内最大剂量为200μg.结果两组的引产成功率分别为95%和93.7%.首次用药至规律宫缩开始时间分别为3.82±1.21h和3.45±1.42h,首次用药至胎儿娩出时间分别为8.60±4.42和8.82±4.87h.两组比较,差异无显著性(P＞0.05).但产后白细胞总数升高B组明显高于A组(P＜0.05).结论采用米索前列醇50μg含服给药法引产,方法更为简便、易行,更为安全有效.     

足月妊娠阴道米索前列醇引产77例分析

我院于１９９６年１０～１２月对７７例足月或过期妊娠孕妇,采用阴道置米索前列醇（简称米索）引产,对其有效性和安全性进行临床观察研究,并抽取６０例同等条件接受催产素引产者临床资料,进行比较分析。１资料与方法１１对象及分组１９９６年１～１２月本院住院分娩...     

米索前列醇用于足月妊娠引产剂量分析

近年来 ,有不少报道米索前列醇用于足月妊娠引产的临床分析 ,而剂量各家报道不一。为了探讨米索前列醇用于足月妊娠引产最适宜剂量 ,我们对 68例足月妊娠孕妇采用阴道置米索前列醇引产 ,剂量分别为 2 5 μｇ或 5 0 μｇ ,观察其临床效果 ,现总结如下。1　资料与方法1 1　一般资料　我院于 1998年 10月至 1999年 8月间 ,对因各种原因需行引产的单胎头位的足月孕妇共 68例 ,经阴道检查排除产道异常 ,无明显头盆不称 ,无米索前列醇禁忌证者随机分两组 :Ⅰ组 3 3例 (初产妇 3 0例 ,经产妇 3例 )阴道置米索前列醇 2 5 μｇ ;Ⅱ组 3 5例 (初产妇 3…     

米索前列醇用于足月妊娠引产1828例疗效观察

综合报道国内１６所医院分娩的初产妇１８２８例，随机分为两组，分别给予米索前列醇和催产素进行足月妊娠引产的病例对照研究。结果：米索前列醇用于足月妊娠的有效率为９３．５６％，显著高于催产素组７９．４９％（Ｐ＜０．０１），其临产发动时间及总产程分别为（２．９５±０．５３）ｈ和（６．３５±２．２１）ｈ，短于催产素组的（３．７５±０．６１）ｈ及（９．０９±２．４１）ｈ（Ｐ＜０．０１）；剖宫产率为８．８９％亦显著低于催产素组１７．０５％（Ｐ＜０．０１）；两组新生儿体重及新生儿窒息发生率均无显著差异（Ｐ＞０．０５）。因此认为：米索前列醇用于足月妊娠引产能缩短产程，降低剖宫产率，有利于计划分娩，是一种安全有效的引产方法。     

口服米索前列醇混悬液用于足月妊娠引产70例分析

目的 探讨小剂量口服米索前列醇混悬液用于足月妊娠引产的有效性和安全性。方法 １４０例有引产指征的足月孕妇分为两组。Ａ组７０例口服米索混悬液,每２ｈ１次,初起每次２０ｍｌ,连续３次后若无规律宫缩出现,第４次起改为每次４０ｍｌ,若出现有效宫缩即停药,否则直至服守２００ｍｌ;Ｂ组７０例静滴催产素引产作为对照组。结果 两组引产成功率分别为８８．５７％和８２．８６％（Ｐ〉０．０５）。Ａ组从开始用药至监产的平     

不同剂量米索前列醇用于足月妊娠引产的临床观察

米索前列醇 (ＭＰ)用于足月妊娠引产 ,已取得了满意效果 ,在国内外已报道较多。但对其副作用 (宫缩过频、胎儿窘迫、子宫破裂、羊水栓塞等 ) ,仍存在顾虑。我们想选用最佳剂量 ,以减少副作用的发生 ,提高阴道分娩的成功率。为此 ,我科对妊娠足月需要引产的孕妇 141例给予阴道后穹窿放置米索前列醇 ,分两组采用不同剂量进行临床观察 ,现报道如下。1　资料与方法1.1　一般资料　选择 1998年 10月至 1999年 4月符合引产指征 (如过期妊娠、羊水过少、妊高征等 )在我科实行计划分娩的孕妇 141例随机分成两组 ,年龄 2 2～ 38岁 ,平均2 6 7岁 ,孕…     

米索前列醇用于足月妊娠引产临床分析

为了进一步探索米索前列醇(简称米索)在足月妊娠引产中的临床应用价值，我院对2002年1月～2004年1月80例足月妊娠宫颈未成熟孕妇随机应用米索和催产素引产，对临床效果总结分析如下。     

小剂量米索前列醇阴道给药用于晚期妊娠引产的临床研究

目的探讨米索前列醇(简称米索)在晚期妊娠(简称晚妊)引产中的作用.方法对50例妊娠38～42周的正常孕妇,有引产指征者,将米索50μg置于阴道后穹窿,抬高臀部0.5 h,并于用药前后观察宫颈长度及宫颈评分的,观察引产效果.结果阴道后穹窿置米索后,宫颈缩短2～3cm,Bishop评分提高4～5分.24h引产成功率达60%,有效率达98%.与对照比较,均有非常显著性差异.结论小剂量米索经阴道给药用于晚期妊娠引产,安全有效.     

米索前列醇在足月妊娠引产中的应用

目的：探讨米索前列醇用于足月妊娠引产的可行性及对母儿的安全性。方法：对８４例足月妊娠单胎头位初产妇，用米索前列醇口服０．１ｍｇ每小时一次，直至胎儿娩出，进行引产（米索组）。以５０例同样条件的孕妇，用催产素引产（催产素组）为对照。结果：米索组及对照组引产成功及有效率分别为９７．６％和８０．０％，Ｐ＜０．０１，有显著性差异。两组１２小时分娩成功率分别为７３．８％与４６．０％，Ｐ＜０．０１，有显著性差异。两组失败率分别为２．４％和２０．０％，Ｐ＜０．０１，有显著性差异。结论：米索前列醇口服用于足月妊娠引产疗效显著、安全、方便，有推广价值     

Titrated oral misoprostol solution versus vaginal misoprostol for labor induction

Objective

To determine the efficacy and safety of a titrated oral misoprostol solution compared with vaginal misoprostol tablets for labor induction.

Methods

A randomized, triple-blind, multicenter clinical trial was conducted between March 2010 and June 2011. Women with a single gestation (n = 200) were randomized to receive a titrated oral misoprostol solution (initial misoprostol dose 20 μg/hour; dose increased by 20 μg/hour every 6 hours up to 80 μg/hour for a maximum of 48 doses) or vaginal misoprostol tablets (25 μg of misoprostol every 6 hours for a maximum of 8 doses). Risk ratios (RR) and 95% confidence intervals (CIs) were calculated for maternal and perinatal outcomes.

Results

The frequencies of vaginal delivery not achieved within 12 hours (RR 0.87; 95% CI, 0.62–1.22) and within 24 hours (RR 1.11; 95% CI, 0.83–1.49) were similar in the 2 groups. No differences were found in terms of uterine hyperstimulation, unfavorable cervix at 12 and 24 hours, oxytocin augmentation, tachysystole, epidural analgesia, adverse effects, and perinatal outcome. Approximately 70% of the women preferred the oral solution.

Conclusion

A titrated oral misoprostol solution was as effective and safe for labor induction as vaginal misoprostol tablets.ClinicalTrial.gov: NCT00 992524     

Oral misoprostol in the third stage of labor.

OBJECTIVE: To compare the efficacy of intravenous ergometrine, intramuscular oxytocin, and oral misoprostol in the control of postpartum hemorrhage. METHODS: Mean blood loss, rates of blood loss between 500 and 1000 ml, hematocrit fall greater than 10%, and need for additional oxytocic agents and nature and rates of adverse effects were assessed in this prospective, randomized, controlled study. RESULTS: All outcomes were similar in the 3 groups. The main adverse effects in the misoprostol group were temperatures higher than 99 degrees F, which normalized within 2 h and shivering, which was mild and self-limiting. CONCLUSIONS: Oral misoprostol is as effective as conventional oxytocic agents in preventing postpartum hemorrhage and can be recommended for use in low-resource settings.     

A prospective randomized study comparing misoprostol and oxytocin for premature rupture of membranes at term

Objective.?The aim of this randomized trial was to compare the efficacy and safety of vaginal misoprostol and oxytocin for cervical ripening and labor induction in patients with premature rupture of membrane (PROM) at term.

Methods.?Ninety-seven women with PROM at term were assigned randomly to receive intravaginal misoprostol or oxytocin. The primary outcome measure was the induction–delivery interval. Secondary outcomes included the number of women who delivered vaginally within 12 hours of the start of the induction in the two groups, the cesarean, hyperstimulation, and failed induction rates, the mode of delivery, and the neonatal outcome.

Results.?Forty-eight women were assigned to intravaginal misoprostol and 49 to oxytocin administration. The mean interval from induction to delivery was 10.61 ± 2.45 hours in the misoprostol group and 11.57 ± 1.91 hours in the oxytocin group (p = 0.063). The rates of vaginal delivery were 83.3% and 87.7% and cesarean delivery were 16.7% and 8.2% in the misoprostol and oxytocin groups, respectively. Neonatal outcomes were not significantly different. Of the cases, 8.3% in the misoprostol group and 8.2% in the oxytocin group revealed uterine contraction abnormalities.

Conclusion.?Our study demonstrates that, intravaginally, misoprostol results in a similar interval from induction of labor to delivery when compared to oxytocin.     

Induction of labor in great grandmultipara with misoprostol

OBJECTIVE: To compare the efficacy and complications of intravaginal misoprostol application with oxytocin infusion for induction of labor in great grandmultiparous pregnancies with a Bishop score of <6. STUDY DESIGN: Sixty-four great grandmultiparous (delivering the tenth, or greater, infant) pregnant patients with a Bishop score of <6 were randomized in two groups with 32 patients receiving 50 microg intravaginal misoprostol four times with 4h intervals, and 32 patients receiving oxytocin infusion for induction of labor starting from 2 mIU/min, increasing it every 30 min with 2 mIU/min increments up to maximum of 40 mIU/min. The time from induction to delivery, the route of delivery, fetal outcome and maternal complications were recorded. Statistical analyses were performed using Mann-Whitney U-test, Chi-Square test and hypothesis test about differences for two proportions (t-test) to determine differences between the two groups. P < or = 0.05 was considered significant. RESULT: The mean time from induction to delivery was 9.91+/-4.30 and 10.88+/-4.72 h in the misoprostol and oxytocin administered group, respectively, with no significant difference between the groups. The rate of vaginal delivery was 84.4 and 87.5% in the misoprostol and oxytocin administered group, respectively, with no significant difference between the groups (P = 0.72). The rates of placental abruption and postpartum hemorrhage were similar in both groups and no case of uterine rupture occurred. The 1 and 5 min mean Apgar scores were 6.91+/-1.57-8.88+/-1.39 and 7.22+/-1.24-9.06+/-0.84 in the misoprostol and oxytocin administered group with no significant differences between the groups (P = 0.38 and 0.51). No case of asphyxia was present. The rate of admission to neonatal intensive care unit was higher in the misoprostol administered group, but the difference was not significant. CONCLUSION: Intravaginal misoprostol is an alternative method to oxytocin in induction of labor in great grandmultiparous pregnant women with low Bishop scores, as it is effective, cheap and easy to use. Safety about rare complications and neonatal morbidity needs clarifications with further studies.     

Uterine rupture associated with use of misoprostol for induction of labor.

The incidence of placenta accreta has increased 10-fold in the past 50 years and now occurs with a frequency of 1 per 2,500 deliveries. Women who have had two or more cesarean deliveries with anterior or central placenta previa have nearly a 40% risk of developing placenta accreta. If the diagnosis or strong suspicion of placenta accreta is formed before delivery, the patient should be counseled about the likelihood of hysterectomy and blood transfusion. Blood products and clotting factors should be available. Cell saver technology shoudd be considered if available as well as the appropriate location and timing for delivery to allow access to adequate surgical personnel and equipment. A preoperative anesthesia assessment should be obtained.     

两种途径米索前列醇用于足月妊娠引产的研究

目的 :探讨米索前列醇用于足月妊娠引产的最佳用药途径。方法 :足月妊娠134例用米索前列醇引产 ,口服组 (A组 ) 69例 ,经阴道组 (B组 ) 65例 ,第 1天上午 9时、下午 3时分别口服或阴道放置米索前列醇 50mg ,未临产者第 2天上午 7时、11时 ,下午 3时重复用药 ,比较两组引产成功率、急产率、胎儿宫内窘迫率、新生儿窒息率及产后出血率。结果 :(1)两组引产成功率分别为 95.7%和 96.9% (P >0 .0 5) ;(2 )急产发生率A组为 2 .9% ,B组为 13.8% (P <0 .0 5) (3)胎儿宫内窘迫A组发生率为 2 .6% ,B组为 13.4 % (P <0 .0 5) ;(4)两组均未发生新生儿窒息及产后大出血。结论 :米索前列醇 50mg口服用于足月妊娠引产安全、有效、方便